The Cancer Letter

Inside information on cancer research and drug development

Vol.
37
No.
4
April 25, 2014Apr 25, 2014
Free
DOWNLOAD THE PDF

FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

ASCO Releases Three Guidelines For Cancer Survivorship Care

NCI CTEP Approved Trials For the Month of April

Login

Looking for IP Login?